{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:27:52Z","timestamp":1762507672157},"reference-count":24,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej18-0545","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T22:38:03Z","timestamp":1549060683000},"page":"271-275","source":"Crossref","is-referenced-by-count":3,"title":["Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis"],"prefix":"10.1507","volume":"66","author":[{"given":"Yoshinori","family":"Yasuda","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya 466-8560, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya 466-8560, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (2013) Primary sclerosing cholangitis. Lancet 382: 1587\u20131599.","DOI":"10.1016\/S0140-6736(13)60096-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, et al. (2011) Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 140: 180\u2013188.","DOI":"10.1053\/j.gastro.2010.10.014"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Collier J (2007) Bone disorders in chronic liver disease. Hepatology 46: 1271\u20131278.","DOI":"10.1002\/hep.21852"},{"key":"4","unstructured":"4 Wills MR, Savory J (1984) Vitamin D metabolism and chronic liver disease. Ann Clin Lab Sci 14: 189\u2013197."},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377: 1276\u20131287.","DOI":"10.1016\/S0140-6736(10)62349-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29: 441\u2013464.","DOI":"10.1210\/er.2008-0002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358: 1474\u20131482.","DOI":"10.1056\/NEJMcp0707217"},{"key":"8","unstructured":"8 Sidlauskas KM, Sutton EE, Biddle MA (2014) Osteoporosis in men: epidemiology and treatment with denosumab. Clin Interv Aging 9: 593\u2013601."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, et al. (2012) Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 91: 225\u2013243.","DOI":"10.1007\/s00223-012-9630-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, et al. (1995) Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95: 2581\u20132586.","DOI":"10.1172\/JCI117959"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Amarasekara DS, Yu J, Rho J (2015) Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. J Immunol Res 2015: 832127.","DOI":"10.1155\/2015\/832127"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Zha L, He L, Liang Y, Qin H, Yu B, et al. (2018) TNF-alpha contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation. Biomed Pharmacother 102: 369\u2013374.","DOI":"10.1016\/j.biopha.2018.03.080"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, et al. (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction. J Exp Med 191: 275\u2013286.","DOI":"10.1084\/jem.191.2.275"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ruscitti P, Cipriani P, Carubbi F, Liakouli V, Zazzeroni F, et al. (2015) The role of IL-1beta in the bone loss during rheumatic diseases. Mediators Inflamm 2015: 782382.","DOI":"10.1155\/2015\/782382"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, et al. (1998) Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28: 695\u2013699.","DOI":"10.1002\/hep.510280315"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Reginato AJ, Coquia JA (2003) Musculoskeletal manifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol 17: 1063\u20131080.","DOI":"10.1016\/j.berh.2003.09.004"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, et al. (2015) Pathogenesis and diagnostic criteria for rickets and osteomalacia\u2014proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society. Endocr J 62: 665\u2013671.","DOI":"10.1507\/endocrj.EJ15-0289"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, et al. (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475\u20131480.","DOI":"10.1172\/JCI119668"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19 Li YC, Amling M, Pirro AE, Priemel M, Meuse J, et al. (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139: 4391\u20134396.","DOI":"10.1210\/en.139.10.4391"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756\u2013765.","DOI":"10.1056\/NEJMoa0809493"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, et al. (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97: 3161\u20133169.","DOI":"10.1210\/jc.2012-1569"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, et al. (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28: 559\u2013566.","DOI":"10.1007\/s00198-016-3764-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, et al. (2014) Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99: 2599\u20132607.","DOI":"10.1210\/jc.2013-4175"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, et al. (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2014a randomized, active comparator, double-blind study. Bone 49: 605\u2013612.","DOI":"10.1016\/j.bone.2011.07.011"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/3\/66_EJ18-0545\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T03:26:24Z","timestamp":1559359584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/3\/66_EJ18-0545\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0545","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}